3-Isopropyldibenzothiophen | 147791-83-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 3-Isopropyldibenzothiophen
• 英文别名: 3-Propan-2-yldibenzothiophene
• CAS: 147791-83-1
• 化学式: C₁₅H₁₄S
• 分子量: 226.342
• InChiKey: VZBHCZXAUIMCGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-Isopropyldibenzothiophen 在 双氧水 、 溶剂黄146 作用下， 反应 0.17h， 以84%的产率得到3-Isopropyldibenzothiophen-5,5-dioxid
  参考文献：
  名称：

  Boberg, Friedrich; Bruns, Wolfgang; Kaller, Rose, Phosphorus, Sulfur and Silicon and the Related Elements, 1992, vol. 72, # 1-4, p. 33 - 48

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(3-Dibenzothiophenyl)-2-propanol 在 palladium on activated charcoal 氢气 、 silica gel 、 copper(II) sulfate 作用下， 以 四氯乙烯 、 乙醇 为溶剂， 反应 0.17h， 生成 3-Isopropyldibenzothiophen
  参考文献：
  名称：

  Boberg, Friedrich; Bruns, Wolfgang; Kaller, Rose, Phosphorus, Sulfur and Silicon and the Related Elements, 1992, vol. 72, # 1-4, p. 33 - 48

  摘要：

  DOI：

文献信息

• Heterocyclic compound and organic light emitting element comprising same
  申请人：LG Chem, Ltd.

  公开号：US10230056B2

  公开（公告）日：2019-03-12

  The present specification provides a heterocyclic compound and an organic light emitting device including the same.

  本规范提供了一种杂环化合物和包括该化合物的有机发光器件。
• COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES
  申请人：Kyulux, Inc.

  公开号：US20190241549A1

  公开（公告）日：2019-08-08

  The present disclosure relates to compounds of Formula (I): C-D   (I) as compounds capable of emitting delayed fluorescence, and uses of the compounds in organic light-emitting diodes.

  本公开涉及式(I)的化合物：C-D   (I)，作为能够发射延迟荧光的化合物，并且该化合物在有机发光二极管中的用途。
• BLUE FLUORESCENT COMPOUNDS AND ORGANIC LIGHT EMITTING DIODE DEVICES USING THE SAME
  申请人：LG Display Co., Ltd.

  公开号：US20140183485A1

  公开（公告）日：2014-07-03

  A blue fluorescent compound is disclosed. The blue fluorescent compound represented by the following Chemical Formula 1, where R1 and R2 are each independently selected from the group consisting of C0-C18 saturated hydrocarbon carbons, branched saturated hydrocarbons, and saturated ring hydrocarbons, and Ar1 and Ar2 are each independently selected from the group consisting of C1-C20 aromatic compounds, heteroaromatic compounds, C1-C18 saturated hydrocarbons, C1-C18 branched saturated hydrocarbons, and C1-C18 saturated ring hydrocarbons.

  本发明揭示了一种蓝色荧光化合物。该蓝色荧光化合物由下列化学式1所表示，其中R1和R2各自独立地选自由C0-C18饱和烃碳、分支饱和烃和饱和环烃组成的群体，而Ar1和Ar2各自独立地选自由C1-C20芳香化合物、杂环芳香化合物、C1-C18饱和烃、C1-C18分支饱和烃和C1-C18饱和环烃组成的群体。
• Azadibenzofurans for electronic applications
  申请人：UDC Ireland Limited

  公开号：US10249827B2

  公开（公告）日：2019-04-02

  The present invention relates to compounds of formula (I), which are characterized in that they substituted by benzimidazo[1,2-a]benzimidazo-5-yl and/or benzimidazo[1,2-a]benzimidazo-2,5-ylene groups and in that at least one of the substituents B1, B2, B3, B4, B5, B6, B7 and B8 represents N; a process for their production and their use in electronic devices, especially electroluminescent devices. When used as host material for phosphorescent emitters in electroluminescent devices, the compounds of formula I may provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.

  本发明涉及式(I)化合物，其特征在于它们被苯并咪唑并[1,2-a]苯并咪唑-5-基和/或苯并咪唑并[1,2-a]苯并咪唑-2,5-亚基取代，且取代基 B1、B2、B3、B4、B5、B6、B7 和 B8 中至少有一个代表 N；本发明还涉及其生产工艺及其在电子设备，尤其是电致发光设备中的应用。当用作电致发光器件中磷光发光体的主材料时，式 I 化合物可提高电致发光器件的效率、稳定性、可制造性或光谱特性。
• Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
  申请人：University of Washington through its Center for Commercialization

  公开号：US10544104B2

  公开（公告）日：2020-01-28

  Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R1, and R3 are defined herein.

  本发明描述了治疗由传染性真核寄生虫弓形虫（T. gondii）引起的弓形虫病和治疗由传染性真核寄生虫副隐孢子虫（C. parvum）和原隐孢子虫（C. hominus）引起的隐孢子虫病的组合物和方法。特别是，本公开涉及使用式中的吡唑嘧啶和/或咪唑并[1,5-a]吡嗪抑制剂抑制刚地隐孢子虫钙依赖性蛋白激酶（TgCDPKs）或副隐孢子虫和人隐孢子虫钙依赖性蛋白激酶（CpCDPKs）的组合物和方法、 其中变量 X、Y、Z、L、R1 和 R3 在本文中定义。